ANNX
Annexon, Inc. NASDAQ Listed Jul 24, 2020$5.52
Mkt Cap $660.2M
52w Low $1.60
70.3% of range
52w High $7.18
50d MA $5.70
200d MA $4.30
P/E (TTM)
-4.3x
EV/EBITDA
-3.0x
P/B
4.2x
Debt/Equity
0.1x
ROE
-97.7%
P/FCF
-4.2x
RSI (14)
—
ATR (14)
—
Beta
1.15
50d MA
$5.70
200d MA
$4.30
Avg Volume
2.6M
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
1400 Sierra Point Parkway · Brisbane, CA 94005 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.32 | -0.28 | +12.5% | 4.96 | +13.7% | +11.7% | -3.2% | +2.6% | +5.5% | +3.3% | — |
| Nov 10, 2025 | AMC | -0.34 | -0.37 | -8.8% | 2.98 | -1.0% | -0.3% | -4.4% | -5.6% | +1.1% | +11.4% | — |
| Aug 14, 2025 | AMC | -0.36 | -0.34 | +5.6% | 2.38 | +2.9% | +2.5% | -3.7% | -6.8% | -2.3% | +1.4% | — |
| May 12, 2025 | AMC | -0.30 | -0.37 | -23.3% | 1.77 | +2.3% | -1.1% | +0.6% | +2.8% | +11.0% | +4.0% | — |
| Mar 3, 2025 | AMC | -0.28 | -0.33 | -17.9% | 2.39 | +0.8% | +3.3% | +11.7% | -2.9% | +3.0% | -5.4% | — |
| Nov 14, 2024 | AMC | -0.26 | -0.25 | +3.8% | 6.33 | +2.5% | -3.3% | -10.8% | +0.0% | -5.5% | +0.2% | — |
| Aug 12, 2024 | AMC | -0.23 | -0.23 | +0.0% | 5.61 | -1.1% | +1.4% | -1.4% | +6.6% | +2.0% | -2.0% | — |
| May 13, 2024 | AMC | -0.32 | -0.21 | +34.4% | 4.87 | +1.8% | -1.0% | -6.6% | -3.1% | -0.7% | +8.1% | — |
| Mar 26, 2024 | AMC | -0.45 | -0.36 | +20.0% | 6.88 | +7.1% | +13.5% | -8.2% | -7.5% | -3.2% | +0.5% | — |
| Nov 13, 2023 | AMC | -0.50 | -0.43 | +14.0% | 2.26 | +5.8% | +9.7% | +1.6% | +1.6% | +1.6% | -0.8% | — |
| Aug 7, 2023 | AMC | -0.54 | -0.47 | +13.0% | 3.45 | -2.0% | -3.2% | +0.3% | +0.0% | -1.2% | -8.5% | — |
| May 8, 2023 | AMC | -0.52 | -0.52 | +0.0% | 5.25 | -0.4% | +4.6% | +2.7% | -2.5% | -0.7% | +11.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Goldman | Initiates | Neutral | $7 | — | — | — | — | — | — | — | — |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $5.49 | $5.45 | -0.7% | -6.9% | +5.1% | -6.9% | +7.4% | -2.2% |
| Nov 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.20 | $3.58 | +11.9% | +26.9% | +5.2% | +0.0% | +5.6% | -1.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.45 | +2.9% | +2.5% | -3.7% | -6.8% | -2.3% | +1.4% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.75 | $1.75 | +0.0% | +0.6% | +2.8% | +11.0% | +4.0% | +0.5% |
| May 13 | Needham | Maintains | Buy → Buy | — | $1.77 | $1.81 | +2.3% | -1.1% | +0.6% | +2.8% | +11.0% | +4.0% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $2.39 | $2.41 | +0.8% | +3.3% | +11.7% | -2.9% | +3.0% | -5.4% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.06 | $5.05 | -0.2% | -3.6% | +1.4% | +5.5% | +0.2% | +1.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.33 | $6.49 | +2.5% | -3.3% | -10.8% | +0.0% | -5.5% | +0.2% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $6.33 | $6.49 | +2.5% | -3.3% | -10.8% | +0.0% | -5.5% | +0.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.61 | $5.55 | -1.1% | +1.4% | -1.4% | +6.6% | +2.0% | -2.0% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $5.61 | $5.55 | -1.1% | +1.4% | -1.4% | +6.6% | +2.0% | -2.0% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.58 | $6.03 | +31.7% | +30.8% | +13.4% | -13.3% | -2.5% | -0.3% |
| Jun 4 | Needham | Maintains | Buy → Buy | — | $4.58 | $6.03 | +31.7% | +30.8% | +13.4% | -13.3% | -2.5% | -0.3% |
| May 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.82 | $4.93 | +2.3% | -6.6% | -3.1% | -0.7% | +8.1% | +2.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.87 | $4.96 | +1.8% | -1.0% | -6.6% | -3.1% | -0.7% | +8.1% |
| May 13 | Needham | Maintains | Buy → Buy | — | $4.75 | $4.95 | +4.2% | +2.5% | -1.0% | -6.6% | -3.1% | -0.7% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $6.17 | $6.40 | +3.7% | -1.6% | -1.5% | -4.0% | -10.8% | -10.4% |
| Apr 1 | JP Morgan | Maintains | Overweight → Overweight | — | $7.17 | $7.10 | -1.0% | -7.5% | -3.2% | +0.5% | -1.1% | -3.0% |
| Apr 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.17 | $7.10 | -1.0% | -7.5% | -3.2% | +0.5% | -1.1% | -3.0% |
| Mar 28 | BofA Securities | Maintains | Buy → Buy | — | $7.81 | $8.00 | +2.4% | -8.2% | -7.5% | -3.2% | +0.5% | -1.1% |
| Mar 27 | Needham | Maintains | Buy → Buy | — | $6.88 | $7.37 | +7.1% | +13.5% | -8.2% | -7.5% | -3.2% | +0.5% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.88 | $7.37 | +7.1% | +13.5% | -8.2% | -7.5% | -3.2% | +0.5% |
| Mar 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $6.88 | $7.37 | +7.1% | +13.5% | -8.2% | -7.5% | -3.2% | +0.5% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $6.40 | +7.2% | -1.7% | -8.9% | -2.1% | -6.3% | +1.2% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $5.97 | $6.40 | +7.2% | -1.7% | -8.9% | -2.1% | -6.3% | +1.2% |
| Mar 1 | JP Morgan | Upgrade | Neutral → Overweight | — | $5.57 | $6.20 | +11.3% | +7.2% | -1.7% | -8.9% | -2.1% | -6.3% |
| Dec 21 | BofA Securities | Upgrade | Neutral → Buy | — | $2.88 | $3.60 | +25.0% | +29.5% | +7.5% | +10.0% | +5.0% | -1.3% |
| Dec 21 | Needham | Maintains | Buy → Buy | — | $2.88 | $3.60 | +25.0% | +29.5% | +7.5% | +10.0% | +5.0% | -1.3% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $2.12 | $2.13 | +0.2% | +6.4% | +9.7% | +1.6% | +1.6% | +1.6% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.85 | $2.87 | +0.7% | +3.5% | +2.4% | -2.0% | -5.7% | +6.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.38 | -2.0% | -3.2% | +0.3% | +0.0% | -1.2% | -8.5% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.45 | $3.38 | -2.0% | -3.2% | +0.3% | +0.0% | -1.2% | -8.5% |
| Aug 1 | Needham | Maintains | Buy → Buy | — | $3.45 | $3.45 | +0.0% | +2.6% | -2.0% | +1.2% | -3.7% | +2.1% |
| Aug 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.45 | $3.45 | +0.0% | +2.6% | -2.0% | +1.2% | -3.7% | +2.1% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $3.32 | +3.4% | +7.5% | +2.6% | -2.0% | +1.2% | -3.7% |
| May 26 | BofA Securities | Downgrade | Buy → Neutral | — | $2.10 | $2.10 | +0.0% | +35.7% | -4.2% | +9.5% | +0.3% | -0.7% |
| May 25 | Needham | Maintains | Buy → Buy | — | $5.17 | $2.83 | -45.3% | -59.4% | +35.7% | -4.2% | +9.5% | +0.3% |
| May 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $2.83 | -45.3% | -59.4% | +35.7% | -4.2% | +9.5% | +0.3% |
| May 25 | JP Morgan | Downgrade | Overweight → Neutral | — | $5.17 | $2.83 | -45.3% | -59.4% | +35.7% | -4.2% | +9.5% | +0.3% |
| May 25 | BTIG | Maintains | Buy → Buy | — | $5.17 | $2.83 | -45.3% | -59.4% | +35.7% | -4.2% | +9.5% | +0.3% |
| May 9 | Needham | Maintains | Buy → Buy | — | $5.25 | $5.23 | -0.4% | +4.6% | +2.7% | -2.5% | -0.7% | +11.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.23 | -0.4% | +4.6% | +2.7% | -2.5% | -0.7% | +11.0% |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $5.15 | $5.14 | -0.2% | +0.8% | +1.3% | +6.7% | +1.4% | -4.0% |
| Mar 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.44 | $4.47 | +0.7% | +1.1% | -6.5% | -1.2% | -1.9% | +0.7% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.41 | $4.50 | +2.0% | +11.3% | +1.8% | -5.4% | -8.0% | +2.1% |
| Mar 7 | Needham | Maintains | Buy → Buy | — | $4.41 | $4.50 | +2.0% | +11.3% | +1.8% | -5.4% | -8.0% | +2.1% |
| Sep 16 | Jefferies | Maintains | Buy → Buy | — | $6.34 | $6.72 | +6.0% | +0.3% | +3.5% | +0.8% | -0.8% | -7.0% |
| Sep 9 | BTIG | Maintains | Buy → Buy | — | $6.02 | $6.25 | +3.8% | +7.1% | -6.7% | +0.5% | +1.5% | +3.3% |
| Aug 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.12 | $6.08 | -0.7% | -4.7% | -3.4% | +0.4% | -3.0% | -7.7% |
No insider trades available.
8-K · 2.02
!! High
Annexon, Inc. -- 8-K 2.02: Earnings Results
Annexon reported Q1 2026 financial results and portfolio progress, providing investors with operational updates and guidance on upcoming clinical development milestones.
May 7
8-K
Unknown — 8-K Filing
I cannot provide a reliable analysis as the filing summary is incomplete and lacks substantive information about the announced developments or their financial impact on ANNX.
Mar 30
8-K
Annexon, Inc. -- 8-K Filing
Annexon's 8-K filing confirms its emerging growth company status under SEC regulations, which allows the biotech firm potential regulatory relief and scaled disclosure requirements.
Feb 17
Data updated apr 24, 2026 6:12pm
· Source: massive.com